Risk Factors for Plasmodium falciparum Recurrence in Artemether Lumefantrine Treated Population from Bushenyi District, Uganda
暂无分享,去创建一个
J. N. Maniga | I. Adebayo | S. Akinola | O. John | Mfitundinda Wilberforce | Katabazi Aziz | Kaweesa Simon Peter | Odoki Martin | Onchoke Vera Bella | Jacqueline Njeri Muchiri | Ochweri Albert
[1] G. Milanez,et al. The high risk of malarial recurrence in patients with Plasmodium-mixed infection after treatment with antimalarial drugs: a systematic review and meta-analysis , 2021, Parasites & vectors.
[2] Jennifer L. Guler,et al. Surveillance of Plasmodium falciparum pfcrt haplotypes in southwestern uganda by high‐resolution melt analysis , 2021, Malaria journal.
[3] O. Doumbo,et al. Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[4] L. Cui,et al. Role of Plasmodium falciparum Kelch 13 Protein Mutations in P. falciparum Populations from Northeastern Myanmar in Mediating Artemisinin Resistance , 2020, mBio.
[5] J. Kaewkungwal,et al. Epidemiological profiles of recurrent malaria episodes in an endemic area along the Thailand-Myanmar border: a prospective cohort study , 2019, Malaria Journal.
[6] J. Augereau,et al. Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination , 2018, Parasite.
[7] A. Aliero,et al. Plasmodium falciparum Malaria Clinical and Parasitological Outcomes after In-vivo Artemether-Lumefantrine (AL) Treatment at Bushenyi District Uganda , 2018 .
[8] L. Duchateau,et al. Zooprophylaxis as a control strategy for malaria caused by the vector Anopheles arabiensis (Diptera: Culicidae): a systematic review , 2017, Infectious Diseases of Poverty.
[9] N. Speybroeck,et al. Micro-epidemiology and spatial heterogeneity of P. vivax parasitaemia in riverine communities of the Peruvian Amazon: A multilevel analysis , 2017, Scientific Reports.
[10] A. Benito,et al. Spatial clustering and risk factors of malaria infections in Bata district, Equatorial Guinea , 2017, Malaria Journal.
[11] T. Horii,et al. Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda , 2017, Malaria Journal.
[12] N. White,et al. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread , 2017, FEMS microbiology reviews.
[13] C. Obua,et al. Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda , 2016, BMC Infectious Diseases.
[14] M. Kulkarni,et al. Plasmodium falciparum malaria parasitaemia among indigenous Batwa and non-indigenous communities of Kanungu district, Uganda , 2016, Malaria Journal.
[15] C. Fontes,et al. Factors associated with recurrent Plasmodium vivax malaria in Porto Velho, Rondônia State, Brazil, 2009. , 2014, Cadernos de saude publica.
[16] O. Amodu,et al. Factors Associated with a Poor Treatment Outcome among Children Treated for Malaria in Ibadan, Southwest Nigeria , 2014, Epidemiology Research International.
[17] R. Cibulskis,et al. World Malaria Report 2013 , 2014 .
[18] L. Okell,et al. Residual Plasmodium falciparum Parasitemia in Kenyan Children After Artemisinin-Combination Therapy Is Associated With Increased Transmission to Mosquitoes and Parasite Recurrence , 2013, The Journal of infectious diseases.
[19] P. Kremsner,et al. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. , 2013, Trends in parasitology.
[20] Y. Berhane,et al. Travel history and malaria infection risk in a low-transmission setting in Ethiopia: a case control study , 2013, Malaria Journal.
[21] R. Price,et al. Early parasitological response following artemisinin-containing regimens: a critical review of the literature , 2013, Malaria Journal.
[22] R. Hallett,et al. Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications , 2012, The American journal of tropical medicine and hygiene.
[23] S. Hoffman,et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.
[24] Renuka Kunte,et al. WHO Guidelines for the treatment of malaria , 2011 .
[25] R. Price,et al. Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] N. Speybroeck,et al. Ranking Malaria Risk Factors to Guide Malaria Control Efforts in African Highlands , 2009, PloS one.
[27] Stephane Proux,et al. Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment , 2009, PloS one.
[28] C. Whitty,et al. Impact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidence , 2007, Malaria Journal.
[29] A. Saul,et al. Zooprophylaxis or zoopotentiation: the outcome of introducing animals on vector transmission is highly dependent on the mosquito mortality while searching , 2003, Malaria Journal.
[30] J. Breman,et al. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. , 2001, The American journal of tropical medicine and hygiene.